TransMedics Group, Inc. (TMDX)
89.98
+3.00
(+3.45%)
USD |
NASDAQ |
Sep 04, 16:00
88.86
-1.12
(-1.24%)
After-Hours: 20:00
TransMedics Group Research and Development Expense (Quarterly) : 31.63M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 31.63M |
| March 31, 2026 | 24.88M |
| December 31, 2025 | 20.70M |
| September 30, 2025 | 15.26M |
| June 30, 2025 | 15.93M |
| March 31, 2025 | 17.16M |
| December 31, 2024 | 16.46M |
| September 30, 2024 | 14.27M |
| June 30, 2024 | 13.86M |
| March 31, 2024 | 11.38M |
| December 31, 2023 | 10.76M |
| September 30, 2023 | 11.13M |
| June 30, 2023 | 8.291M |
| March 31, 2023 | 5.871M |
| December 31, 2022 | 5.756M |
| September 30, 2022 | 6.808M |
| June 30, 2022 | 6.714M |
| March 31, 2022 | 7.534M |
| December 31, 2021 | 6.314M |
| Date | Value |
|---|---|
| September 30, 2021 | 5.163M |
| June 30, 2021 | 6.295M |
| March 31, 2021 | 4.532M |
| December 31, 2020 | 4.548M |
| September 30, 2020 | 4.155M |
| June 30, 2020 | 3.903M |
| March 31, 2020 | 6.225M |
| December 31, 2019 | 6.262M |
| September 30, 2019 | 4.939M |
| June 30, 2019 | 4.787M |
| March 31, 2019 | 3.882M |
| December 31, 2018 | 3.486M |
| September 30, 2018 | 3.272M |
| June 30, 2018 | 3.433M |
| March 31, 2018 | 3.465M |
| December 31, 2017 | 3.401M |
| September 30, 2017 | 3.402M |
| June 30, 2017 | 4.193M |
| March 31, 2017 | 3.961M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alphatec Holdings, Inc. | 18.17M |
| Boston Scientific Corp. | 554.00M |
| Artivion, Inc. | 9.055M |
| Insulet Corp. | 88.10M |
| Teleflex, Inc. | 45.12M |